| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
Loliolid does not have a well-defined single therapeutic target but exhibits multiple biological activities. It functions as a carotenoid metabolite and a potential endogenous inducer of herbivore resistance. The compound inhibits seedling growth and acts as a germination inhibitor. It also serves as a repellent for ants (Atta cephalotes). Loliolid has cytostatic activity against carcinoma and leukemia cells. Its mechanism of action may involve modulation of cellular signaling pathways, although specific targets are not well-characterized.
|
|---|---|
| ln Vitro |
Loliolid exhibits cytostatic activity against carcinoma and leukemia cells. It functions as a germination inhibitor and a repellent for ants. The compound is a carotenoid metabolite and a potential endogenous inducer of herbivore resistance. Loliolid also inhibits seedling growth. As a monoterpene lactone belonging to the benzofuran class, it has diverse biological activities. The compound's cytostatic activity suggests potential for further investigation as an anticancer agent.
|
| ln Vivo |
In vivo activity data for loliolid are limited. The compound has been studied for its role as a germination inhibitor and herbivore resistance inducer in plants. It has cytostatic activity against carcinoma and leukemia cells, suggesting potential anticancer properties. However, specific in vivo efficacy studies in animal models are not well-documented in the public domain. The compound is primarily studied for its ecological roles and potential pharmacological activities.
|
| Enzyme Assay |
In vitro assays for loliolid typically involve testing its cytostatic activity against cancer cell lines. Cells (such as carcinoma or leukemia cell lines) are treated with varying concentrations of loliolid (typically 0.1-100 μM) for 24-72 hours. Cell viability is assessed using MTT, CCK-8, or trypan blue exclusion assays. The compound's effects on cell proliferation, cell cycle distribution, and apoptosis are evaluated using flow cytometry and other standard methods. The compound is dissolved in DMSO or ethanol and diluted in cell culture medium.
|
| Cell Assay |
In vitro cellular assays for loliolid typically involve treating cancer cell lines (such as carcinoma or leukemia cells) with the compound at concentrations ranging from 0.1 to 100 μM for 24-72 hours. Cell viability is assessed using MTT, CCK-8, or CellTiter-Glo assays. Cell cycle distribution is analyzed by flow cytometry after propidium iodide staining. Apoptosis is assessed using Annexin V/PI staining or caspase activity assays. The compound is dissolved in DMSO as a stock solution and diluted in cell culture medium, with DMSO-only treated cells serving as controls.
|
| Animal Protocol |
In vivo animal studies for loliolid are not extensively documented. For potential in vivo applications, the compound could be administered to mice via oral gavage or intraperitoneal injection at doses determined from preliminary studies. Tumor xenograft models using carcinoma or leukemia cell lines could be used to evaluate antitumor efficacy. The compound's effects on tumor growth, metastasis, and survival would be assessed. However, specific protocols for in vivo studies with loliolid are not well-established in the public domain.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of loliolid are not extensively documented. The compound has a molecular weight of 196.24 g/mol and formula C11H16O3. It is a monoterpene lactone belonging to the benzofuran class. The compound is typically stored at -20°C. Detailed PK parameters such as half-life, Cmax, AUC, and bioavailability would require experimental determination. The compound is soluble in organic solvents such as DMSO and ethanol.
|
| Toxicity/Toxicokinetics |
Toxicity data for loliolid are not extensively reported. The compound is intended for research use only and is not approved for human therapeutic applications. As a naturally occurring compound, it may have a favorable safety profile, but appropriate safety precautions should be taken when handling. Standard toxicity assessments would include acute toxicity, genotoxicity, and repeated-dose toxicity studies. The compound's cytostatic activity suggests potential effects on cell proliferation that could be relevant for toxicity assessment.
|
| References | |
| Additional Infomation |
Loliolide belongs to the benzofuran class of compounds and is a metabolite. It has been reported to exist in Erythrophleum fordii, Otanthus maritimus, and other organisms with relevant data. See also: Acai berry pulp (partial).
Loliolid (CAS 5989-02-6) is a monoterpene lactone and a member of the benzofuran class of compounds. It has a molecular weight of 196.24 g/mol and formula C11H16O3. The compound is a bioactive natural product derived from various plants including Lolium perenne and Artemisia ludoviciana. Loliolid functions as a carotenoid metabolite, germination inhibitor, ant repellent, and has cytostatic activity against carcinoma and leukemia cells. It is also known as loliolide. The compound is not approved for clinical use. |
| Molecular Formula |
C11H16O3
|
|---|---|
| Molecular Weight |
196.24294
|
| Exact Mass |
196.11
|
| CAS # |
5989-02-6
|
| PubChem CID |
100332
|
| Appearance |
White to off-white solid powder
|
| Density |
1.16±0.1 g/cm3(Predicted)
|
| Boiling Point |
352.7±42.0 °C(Predicted)
|
| Melting Point |
151-153℃
|
| LogP |
1.409
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
14
|
| Complexity |
317
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
C[C@@]12C[C@H](CC(C1=CC(=O)O2)(C)C)O
|
| InChi Key |
XEVQXKKKAVVSMW-WRWORJQWSA-N
|
| InChi Code |
InChI=1S/C11H16O3/c1-10(2)5-7(12)6-11(3)8(10)4-9(13)14-11/h4,7,12H,5-6H2,1-3H3/t7-,11+/m0/s1
|
| Chemical Name |
(6S,7aR)-6-hydroxy-4,4,7a-trimethyl-6,7-dihydro-5H-1-benzofuran-2-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.0958 mL | 25.4790 mL | 50.9580 mL | |
| 5 mM | 1.0192 mL | 5.0958 mL | 10.1916 mL | |
| 10 mM | 0.5096 mL | 2.5479 mL | 5.0958 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
